Clinical Trial Update: TAS102 in Combination With NAL-IRI in Advanced GI Cancers [Phase 1, Phase 2]

View source ↗

Summary

This document provides an update on an ongoing Phase 1/2 clinical trial evaluating the combination of TAS-102 with nanoliposomal irinotecan (NAL-IRI) in advance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma
• Colorectal Cancer
• Gastric Cancer
• Pancreatic Cancer

Drugs mentioned

• Lonsurf (trifluridine/tipiracil)
• Onivyde (irinotecan hydrochloride liposome injection)

Snippet

Sponsor: Emory University | Conditions: Colorectal Adenocarcinoma, Gastric Adenocarcinoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING